BPA - HPLC/UHPLC and GC-MS Systems

The Food and Drug Administration is forecasting the acquisition of new HPLC/UHPLC and GC-MS systems under a Blanket Purchase Agreement with a base period and four optional years. These advanced analytical instruments are intended to significantly enhance laboratory operations by increasing sample throughput, reducing analysis times, and enabling the simultaneous processing of multiple samples. The upgraded systems will improve efficiency in complex chemical analyses such as multi-residue screening and targeted quantitative methods, directly supporting regulatory decision-making through faster turnaround times for samples. Modern instrumentation will also deliver superior sensitivity, selectivity, and reliability, strengthening the quality and defensibility of analytical results that underpin FDA’s regulatory actions. The procurement is aligned with NAICS code 334516 and is being managed by the FDA’s Office of Laboratory Operations and Analysis Services, with program inquiries directed to hfpacquisitions@fda.hhs.gov. The contracting officer role is currently undetermined.